648 results on '"van Besien, K."'
Search Results
2. Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors
3. Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task
4. Non-Hodgkin’s Lymphoma
5. Against the odds: haplo-cord grafts protect from GvHD and relapse
6. S114: FEASIBILITY OF HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS WITH SEVERE SICKLE CELL DISEASE WITH END-STAGE RENAL DISEASE (ESRD) ON HEMODIALYSIS
7. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients
8. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes
9. Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis
10. Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation
11. A strategy to reduce donor-specific HLA Abs before allogeneic transplantation
12. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML
13. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation
14. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance
15. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation
16. Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy.
17. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning
18. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
19. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes
20. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience
21. Stem cell transplantation in follicular lymphoma: progress at last?
22. Regimen-related toxicity after fludarabine–melphalan conditioning: a prospective study of 31 patients with hematologic malignancies
23. Safety and outcome after fludarabine–thiotepa–TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies
24. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir
25. Single cord blood transplantation combined with an HLA mismatched third party donor for high-risk haematological patients and HIV infection: O389
26. Allogeneic and autologous transplantation for chronic lymphocytic leukemia
27. Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions
28. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant
29. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR)
30. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival
31. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease
32. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant
33. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation
34. Toxicity of single daily dose gentamicin in stem cell transplantation
35. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia
36. Reduced-intensity haplo cord transplant: O160
37. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab
38. Breakthrough bloodstream infections caused by echinocandin-resistant candida tropicalis: An emerging threat to immunocompromised patients with hematological malignancies
39. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir
40. Allogeneic blood stem cell transplantation in advanced hematologic cancers
41. Detection and Characterization of Influenza B Virus With Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient
42. Unrelated donor transplantation over the age of 55. Are we merely getting (b)older?
43. Chimerism does not predict for outcome after alemtuzumab based conditioning
44. Severe intestinal graft-versus-host disease following autologous stem cell transplantation
45. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
46. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma
47. Clinical activity of arsenic trioxide in Burkitt-like lymphoma
48. Pilot Trial of Interleukin-2 With Granulocyte Colony-Stimulating Factor for the Mobilization of Progenitor Cells in Advanced Breast Cancer Patients Undergoing High-Dose Chemotherapy: Expansion of Immune Effectors Within the Stem-Cell Graft and Post–Stem-Cell Infusion
49. CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS
50. MULTI-CENTER PHASE II STUDY OF ORAL AZACITIDINE (CC-486) PLUS CHOP AS INITIAL TREATMENT FOR PERIPHERAL T-CELL LYMPHOMA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.